King-Jones Heidy sold SYRE
October 1, 2026 · Form 4 insider transaction
King-Jones Heidy sold 400 shares of Spyre Therapeutics, Inc. at $89.24 per share, a transaction worth $35.7K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Footnotes
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.; The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.